Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Antipsychotic drugs. --- Antipsychotic agents --- Antipsychotics --- Major tranquilizers --- Major tranquilizing agents --- Major tranquilizing drugs --- Neuroleptic agents --- Neuroleptic drugs --- Neuroleptics --- Neurolepts --- Tranquilizing drugs, Major --- Psychotropic drugs --- Psychoses --- Chemotherapy

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book provides clear and concise guidance for clinicians when they encounter a patient with psychosis, starting with the medical work-up to arrive at a diagnosis and ending with the comprehensive care for patients with established schizophrenia. It covers the optimal use of medications (emphasizing safe use) but also addresses other treatment approaches (psychological treatments, rehabilitation) and the larger societal context of care, including how to work effectively in complex systems. It uniquely condenses the literature into teaching points without simplifying too much, effectively serving as a learning tool for trainees and professionals. For this second edition, the book was extensively updated and its content expanded, with new figures as well. Each chapter begins with an initial summary and includes Tips and Key Points in text boxes. Each chapter also includes links to external websites and additional readings. The book contains clinical and practical wisdom for clinicians who are treating real patients at the front lines, setting it apart from all other texts. Psychotic Disorders is an excellent resource for medical students, early career professionals such as trainees and fellows, and related clinicians seeking additional training and resources, including those in psychiatry, psychology, neurology, and all others.

Schizophrenia --- Antipsychotic drugs --- Diagnosis. --- Therapy. --- Therapeutic use. --- Antipsychotic agents --- Antipsychotics --- Major tranquilizers --- Major tranquilizing agents --- Major tranquilizing drugs --- Neuroleptic agents --- Neuroleptic drugs --- Neuroleptics --- Neurolepts --- Tranquilizing drugs, Major --- Psychotropic drugs --- Psychoses --- Dementia praecox --- Schizophrenic disorders --- Schizotypal personality disorder --- Chemotherapy --- Psychiatry. --- Medicine and psychology --- Mental health --- Psychology, Pathological

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceutical development must now focus on complementary or even alternative mechanisms of action to address unmet medical  needs, i.e. poorly treated domains of schizophrenia, improved acceptance by patients, better adherence to medication, safety in psychoses in demented patients, and avoiding cardiac and metabolic adverse effects. The first completely novel mechanisms evolving from our insights into the pathophysiology of psychotic disorders, especially the role of glutamatergic mechanisms in schizophrenia, are now under development, and further principles are on the horizon. This situation, in many respects similar to that when the initial second-generation antipsychotics became available, can be rewarding for all.  Preclinical and clinical researchers now have the opportunity to confirm their hypotheses and the pharmaceutical industry may be able to develop really novel classes of therapeutics. When we were approached by the publishers of the Handbook of Experimental Pharmacology to prepare a new volume on antipsychotics, our intention was to capture both, the accumulated preclinical and clinical knowledge about current antipsychotics as well as prospects for new and potentially more specific antischizophrenia principles. These efforts should be based on the pathophysiology of the diseases and the affected neurotransmitter systems. Since preclinical research on antipsychotic compounds is only reliable when intimately linked through translational aspects to clinical results, we decided to include clinical science as well. It turned out that that this endeavor could not be covered by a single volume. We thank the editorial board and the publishers for supporting our decision to prepare two volumes: Current Antipsychotics and Novel Antischizophrenia Treatments. These topics cannot really be separated from one another and should be seen as a composite entity despite the somewhat arbitrary separation of contributions into two volumes. The continuing challenges of developing improved and safer antipsychotic medications remain of concern and are discussed in the first volume. The new opportunities for the field to develop and license adjunctive treatments for the negative symptoms and cognitive deficits that are treated inadequately by existing compounds have been incentivized recently and provide the focus for the second volume. We hope these collective contributions will facilitate the development of improved treatments for the full range of symptomatology seen in the group of schizophrenias and other major psychotic disorders. Gerhard Gross, Ludwigshafen, Germany Mark A. Geyer, La Jolla, CA This volume will try to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters will also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. Non-schizophrenia indications will be covered to some extent, but not exhaustively.

Antipsychotic agents -- Therapeutic use. --- Antipsychotic drugs -- Controlled release. --- Injections. --- Antipsychotic drugs --- Tranquilizing Agents --- Schizophrenia and Disorders with Psychotic Features --- Therapeutics --- Psychotropic Drugs --- Central Nervous System Depressants --- Mental Disorders --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Central Nervous System Agents --- Physiological Effects of Drugs --- Psychiatry and Psychology --- Pharmacologic Actions --- Therapeutic Uses --- Chemical Actions and Uses --- Chemicals and Drugs --- Antipsychotic Agents --- Drug Therapy --- Psychotic Disorders --- Health & Biological Sciences --- Pharmacy, Therapeutics, & Pharmacology --- Antipsychotic drugs. --- Antipsychotic agents --- Antipsychotics --- Major tranquilizers --- Major tranquilizing agents --- Major tranquilizing drugs --- Neuroleptic agents --- Neuroleptic drugs --- Neuroleptics --- Neurolepts --- Tranquilizing drugs, Major --- Medicine. --- Pharmacy. --- Neurosciences. --- Pharmacology. --- Behavioral sciences. --- Proteins. --- Neurobiology. --- Biomedicine. --- Pharmacology/Toxicology. --- Receptors. --- Behavioral Sciences. --- Psychotropic drugs --- Psychoses --- Chemotherapy --- Toxicology. --- Cell receptors. --- Animal behavior. --- Chemistry --- Medicine --- Drugs --- Materia medica --- Pharmacology --- Animals --- Animals, Habits and behavior of --- Behavior, Animal --- Ethology --- Animal psychology --- Zoology --- Ethologists --- Psychology, Comparative --- Neurosciences --- Cell membrane receptors --- Cell surface receptors --- Receptors, Cell --- Binding sites (Biochemistry) --- Cell membranes --- Proteins --- Neural sciences --- Neurological sciences --- Neuroscience --- Medical sciences --- Nervous system --- Chemicals --- Poisoning --- Poisons --- Behavior --- Toxicology --- Proteins . --- Proteids --- Biomolecules --- Polypeptides --- Proteomics --- Drug effects --- Medical pharmacology --- Pharmacy --- Physiological effect

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Adverse drug reactions are one of the major constraints when using drugs. These adverse reactions can impact healthcare systems as strongly as many prevalent diseases. Identifying DNA variants associated with adverse drug reactions can help personalize medicine and sustain healthcare systems. This book delves into new advances in pharmacogenetics of cardiovascular, cancer, and nervous system drugs. It may be useful for clinicians and patients to understand the basics of pharmacogenetics.

5-fluorouracil --- capecitabine --- fluoropyrimidine --- thymidylate synthase --- thymidylate synthase enhancer region --- upstream stimulatory factor 1 --- adverse drug reactions --- pharmacogenomics --- epistasis --- random forest --- statin --- cardiovascular disease --- colorectal cancer --- personalised medicine --- toxicity --- (es)citalopram --- drug-gene-interaction --- drug-drug-interaction --- drug-drug-gene-interaction --- the PharmLines initiative --- antipsychotic agents --- pharmacogenetics --- cytochrome P-450 enzyme system --- psychotic disorders --- precision medicine --- direct oral anticoagulants --- clinical implementation --- atorvastatin --- SLCO1B1 --- HLA --- cutaneous adverse drug reaction --- SCAR --- genetic polymorphism --- antiepileptics --- CYP450 enzymes --- platelet reactivity --- single-nucleotide variants --- acute coronary syndrome --- clopidogrel --- genotype --- allele --- polymorphism --- HLA B --- CYP2C9*3 --- cutaneous adverse drug reactions (CADRs) --- anti-epileptic drugs (AEDS) --- phenytoin (PHT) --- genetic risk factors --- South India --- India --- cardiology --- adverse events --- guidelines --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Geneesmiddelen --- Médicaments --- Psychiatrie --- Therapieën --- Thérapies --- Psychotic Disorders --- Behavior Therapy. --- Antipsychotic Agents --- Patient Compliance. --- #KVHB:Psychiatrie --- #KVHB:Psychofarmaca --- #KVHB:Psychose --- 607.1 --- libermanmodules --- psychofarmaca --- psychose --- rollenspel --- 364.444 --- 616.89 --- Psychiatrische patienten : maatschappelijke integratie --- psychiatrie --- psychiatrische patiënt --- psychiatrische verpleegkunde --- psychotherapie --- vaardigheidstraining --- Patient Non-Adherence --- Patient Non-Compliance --- Patient Nonadherence --- Patient Adherence --- Patient Cooperation --- Patient Noncompliance --- Adherence, Patient --- Compliance, Patient --- Cooperation, Patient --- Non-Adherence, Patient --- Non-Compliance, Patient --- Nonadherence, Patient --- Noncompliance, Patient --- Patient Non Adherence --- Patient Non Compliance --- Treatment Refusal --- Directly Observed Therapy --- Therapy, Behavior --- Therapy, Conditioning --- Behavior Modification --- Conditioning Therapy --- Behavior Modifications --- Behavior Therapies --- Conditioning Therapies --- Modification, Behavior --- Modifications, Behavior --- Therapies, Behavior --- Therapies, Conditioning --- Mind-Body Therapies --- Behavior Control --- psychology. --- therapeutic use. --- Lichamelijke behandelingsmethoden --- Therapeutic Compliance --- Treatment Compliance --- Compliance, Therapeutic --- Compliance, Treatment --- Compliances, Therapeutic --- Therapeutic Compliances --- Treatment Compliances --- Behavior Therapy --- Patient Compliance --- psychology --- therapeutic use --- Behavior Treatment --- Treatment, Behavior --- Client Adherence --- Client Compliance --- Non-Adherent Patient --- Adherence, Client --- Client Compliances --- Compliance, Client --- Non Adherent Patient --- Non-Adherent Patients --- Patient, Non-Adherent --- Behavior Change Techniques --- Behavior Change Technique --- Technique, Behavior Change